Ward Greenberg represents Fortune 500 companies and regional manufacturers, suppliers, and providers of technically sophisticated medical devices and specialized pharmaceuticals. Our attorneys’ extensive litigation experience in this field gives us the knowledge and expertise necessary to handle the complex claims that are unique to medical device and pharmaceutical clients.
We understand that to be successful with these types of claims, you must become an expert in the specific drug, product, or device at issue. Clients trust our command of the facts, case law, and regulations. They also value our focused strategy for efficiently and successfully resolving matters.
- Successfully assisting in defense of multinational pharmaceutical company in personal injury matter alleging that Hodgkin’s Lymphoma resulted from topical dermatological use of a prescription ointment.
- Representing large pharmaceutical wholesaler as national counsel in PPA litigation, including the MDL and several state mass tort programs.
- Obtaining summary judgment after expert depositions in failure to warn case involving failure to refrigerate chemotherapy drug unsuccessfully used to treat prostate cancer.
- Representing multinational pharmaceutical manufacturer in HRT litigation in mass tort programs in Pennsylvania and New Jersey.
- Representing large pharmaceutical manufacturer in multidistrict litigation seeking recovery for allegedly fraudulent pricing practices.
- Representing medical laser manufacturer in resolving design defect/failure to warn claims that allegedly caused patient to sustain burns following treatment.
- Representing medical device manufacturing corporations in state and federal court in product liability actions involving medical devices such as prosthetic knee replacement systems, cervical interbody fusion systems, percutaneous sheath introducer (PSI)-catheter, and automated external defibrillator.
- Representing national pharmaceutical distributor in multiple products liability cases pending in New York State court alleging strict liability, negligence, breach of warranty, fraud, and violation of New York State General Business Law concerning the marketing and distribution of national, brand-named drug.
- Representing publicly traded biotechnology and pharmaceutical companies as local counsel in a wrongful death/product liability action involving an FDA-approved drug for the treatment of multiple sclerosis. See Amos v. Biogen IDEC Inc., 249 F.Supp. 3d 690 (W.D.N.Y. 2017).